Ionis Pharmaceuticals Inc (NASDAQ: IONS) is -16.60% lower on its value in year-to-date trading and has touched a low of $35.95 and a high of $54.44 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IONS stock was last observed hovering at around $41.02 in the last trading session, with the day’s gains setting it 1.17%.
Currently trading at $42.19, the stock is -9.95% and -11.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.23 million and changing 2.85% at the moment leaves the stock -7.97% off its SMA200. IONS registered -2.22% loss for a year compared to 6-month gain of 0.02%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.95% loss in the last 1 month and extending the period to 3 months gives it a 2.60%, and is -10.02% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.51% over the week and 3.34% over the month.
Ionis Pharmaceuticals Inc (IONS) has around 927 employees, a market worth around $6.65B and $813.95M in sales. Profit margin for the company is -44.90%. Distance from 52-week low is 17.36% and -22.51% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.64%).
The EPS is expected to shrink by -38.56% this year.
Ionis Pharmaceuticals Inc (IONS) Top Institutional Holders
508.0 institutions hold shares in Ionis Pharmaceuticals Inc (IONS), with institutional investors hold 96.56% of the company’s shares. The shares outstanding are 157.71M, and float is at 144.60M with Short Float at 7.03%. Institutions hold 95.81% of the Float.
The top institutional shareholder in the company is FMR LLC with over 21.89 million shares valued at $1.04 billion. The investor’s holdings represent 15.044% of the IONS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.85 million shares valued at $659.89 million to account for 9.5135 of the shares outstanding. The other top investors are T. ROWE PRICE INVESTMENT MANAGEMENT, INC. which holds 12.64 million shares representing 8.6848% and valued at over $602.41 million, while BLACKROCK INC. holds 7.0916 of the shares totaling 10.32 million with a market value of $491.9 million.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
The most recent transaction is an insider sale by Geary Richard S, the company’s EVP, Chief Development Officer. SEC filings show that Geary Richard S sold 331 shares of the company’s common stock on Aug 29 ’24 at a price of $49.63 per share for a total of $16428.0. Following the sale, the insider now owns 84823.0 shares.
Ionis Pharmaceuticals Inc disclosed in a document filed with the SEC on Aug 28 ’24 that Geary Richard S (EVP, Chief Development Officer) sold a total of 320 shares of the company’s common stock. The trade occurred on Aug 28 ’24 and was made at $49.16 per share for $15731.0. Following the transaction, the insider now directly holds 85154.0 shares of the IONS stock.
Still, SEC filings show that on Aug 05 ’24, Geary Richard S (EVP, Chief Development Officer) disposed off 2,430 shares at an average price of $48.00 for $0.12 million. The insider now directly holds 85,508 shares of Ionis Pharmaceuticals Inc (IONS).
